ORIC PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ORIC PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 30.98K shares, a 296.52% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 253.85K shares, a 378.88% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 184.93K shares, a 7940.57% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 144.30K shares, a 445.87% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 390.06K shares, a 156.26% increase from fiscal 2024.
- ORIC PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 152.21K shares, a 1023.49% increase from fiscal 2023.
- ORIC PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 13.55K shares, a 71.82% decline from fiscal 2022.
- ORIC PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 48.08K shares, a 70.01% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 30.98K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | 614.06K shares derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | 253.85K shares 10-Q · filed 2026-05-04 | 590.89K shares derived: sum of 4 quarters · filed 2026-05-04 |
| 2025-12-31 | 184.93K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | 390.06K shares 10-K · filed 2026-02-23 |
| 2025-09-30 | 144.30K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | 207.42K shares derived: sum of 4 quarters · filed 2025-11-13 |
| 2025-06-30 | 7.81K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 89.56K shares derived: sum of 4 quarters · filed 2025-08-12 |
| 2025-03-31 | 53.01K shares 10-Q · filed 2025-05-05 | 153.68K shares derived: sum of 4 quarters · filed 2025-05-05 |
| 2024-12-31 | 2.30K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | 152.21K shares 10-K · filed 2025-02-18 |
| 2024-09-30 | 26.43K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 156.27K shares derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | 71.94K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | 137.01K shares derived: sum of 4 quarters · filed 2024-08-12 |
| 2024-03-31 | 51.54K shares 10-Q · filed 2024-05-06 | 65.07K shares derived: sum of 4 quarters · filed 2024-05-06 |
| 2023-12-31 | 6.36K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | 13.55K shares 10-K · filed 2024-03-11 |
| 2023-09-30 | 7.17K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | 7.78K shares derived: sum of 4 quarters · filed 2023-11-06 |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 1.20K shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | 16.00 shares 10-Q · filed 2023-05-08 | 39.61K shares derived: sum of 4 quarters · filed 2023-05-08 |
| 2022-12-31 | 594.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | 48.08K shares 10-K · filed 2023-03-16 |
| 2022-09-30 | 593.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | 146.02K shares derived: sum of 4 quarters · filed 2022-11-07 |
| 2022-06-30 | 38.41K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 164.00K shares derived: sum of 4 quarters · filed 2022-08-11 |
| 2022-03-31 | 8.48K shares 10-Q · filed 2022-05-09 | 150.37K shares derived: sum of 4 quarters · filed 2022-05-09 |
| 2021-12-31 | 98.53K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | 160.30K shares 10-K · filed 2022-03-21 |
| 2021-09-30 | 18.57K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | 109.76K shares derived: sum of 4 quarters · filed 2021-11-08 |
| 2021-06-30 | 24.79K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | 123.66K shares derived: sum of 4 quarters · filed 2021-08-10 |
| 2021-03-31 | 18.41K shares 10-Q · filed 2021-05-06 | 122.07K shares derived: sum of 4 quarters · filed 2021-05-06 |
| 2020-12-31 | 47.99K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23 | 117.09K shares 10-K · filed 2021-03-23 |
| 2020-09-30 | 32.47K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | |
| 2020-06-30 | 23.20K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | |
| 2020-03-31 | 13.43K shares 10-Q · filed 2020-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |